Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 5:25:100635.
doi: 10.1016/j.ymgmr.2020.100635. eCollection 2020 Dec.

Behavioral, social and school functioning in children with Pompe disease

Aditi Korlimarla  1 , Gail A Spiridigliozzi  2 , Mihaela Stefanescu  1 , Stephanie L Austin  1 , Priya S Kishnani  1
Affiliations

Behavioral, social and school functioning in children with Pompe disease

Aditi Korlimarla et al. Mol Genet Metab Rep. .

Abstract

Purpose: To improve our understanding of the behavioral, social, and emotional functioning of children and adolescents with Pompe disease.

Method: Parents/guardians of 21 children (age 5-18y) with infantile (IPD) or late-onset (LOPD) Pompe disease on long-term enzyme replacement therapy completed three standardized checklists regarding their child's behavior: the Child Behavior Checklist (CBCL), Conners 3 Parent (Conners-3), Behavior Rating Inventory of Executive Function-2 (BRIEF2), and a survey of their child's educational services.

Results: Descriptive statistics were used to summarize the findings for each behavior checklist. Age standard scores from each checklist were reported for the IPD (n = 17, 9 females, mean age = 9y, 4 mo; SD = 3y, 8mo) and LOPD (n = 4, 1 female; mean = 11y, 2mo; SD = 2y, 1mo) groups. The majority of children with Pompe exhibited age-appropriate behavior and emotional functioning on these standardized checklists. However, negative mood symptoms, learning problems, decreased participation in structured social activities, and attentional difficulties were more frequently reported in children with IPD in comparison to same-aged peers. Parents of children with LOPD reported fewer problematic behaviors but endorsed negative mood symptoms and difficulties with peer relations. Most children received accommodations in regular education classrooms at school.

Conclusions: These standardized behavior checklists are useful screening tools for the early identification and treatment of behavior, emotional, and social concerns in children with Pompe disease.

Keywords: ADHD, attention-deficit/hyperactivity disorder; BRIEF2, Behavior Rating Inventory of Executive Function-Second Edition; Behavior checklists; CBCL, Child Behavior Checklist; Children with Pompe disease; Conners-3, Conners 3rd Edition Parent; ERT, enzyme replacement therapy; Emotional functioning; GAA, acid alpha-glucosidase; IEP, Individualized Education Program; IPD, infantile Pompe disease; LOPD, late-onset Pompe disease; SD, standard deviation; School functioning; Screening for behavior problems; Social functioning.

PubMed Disclaimer

Conflict of interest statement

Dr. Aditi Korlimarla, Dr. Gail A. Spiridigliozzi, Mihaela Stefanescu, and Stephanie L. Austin have stated that they had no interests which might be perceived as posing a conflict or bias. Dr. Priya S. Kishnani has received research/grant support from 10.13039/100004339Sanofi Genzyme, 10.13039/100012638Valerion Therapeutics, and 10.13039/100015362Amicus Therapeutics. She has received consulting fees and honoraria from Sanofi Genzyme, Amicus Therapeutics, Vertex Pharmaceuticals and Asklepios Biopharmaceutical, Inc. (AskBio). She is a member of the Pompe and Gaucher Disease Registry Advisory Board for Sanofi Genzyme, Amicus Therapeutics, and Baebies. She has equity in Asklepios Biopharmaceutical, Inc. (AskBio), which is developing gene therapy for Pompe disease.

Figures

Fig. 1
Fig. 1
Lightest shade (T-scores <60, normal), moderately shaded areas (T-scores = 60–69, clinically relevant) and darkest shade (T-scores ≥70, clinically significant). The only exception was for the CBCL Competence scales, where the lightest shade (T-scores ≥40, normal), moderately shaded areas (T-scores = 31–39, clinically relevant) and darkest shade (T-scores ≤30, clinically significant).
Fig. 2
Fig. 2
Numerator indicates number of children with clinically relevant/significant scores on a scale, and the denominator indicates the total number of children with completed scale scores. All scales from one particular behavior checklist have a unique color (green is for CBCL, orange is for Conners-3, and dark blue is for BRIEF2).
See this image and copyright information in PMC

References

    1. Kishnani P.S., Corzo D., Nicolino M., Byrne B., Mandel H., Hwu W.L. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68(2):99–109. - PubMed
    1. Kishnani P.S., Steiner R.D., Bali D., Berger K., Byrne B.J., Case L.E. Pompe disease diagnosis and management guideline. Genetics in medicine : official journal of the American College of Medical Genetics. 2006;8(5):267–288. - PMC - PubMed
    1. Chan J., Desai A.K., Kazi Z.B., Corey K., Austin S., Hobson-Webb L.D. The emerging phenotype of late-onset Pompe disease: a systematic literature review. Mol. Genet. Metab. 2017;120(3):163–172. - PubMed
    1. Korlimarla A., Spiridigliozzi G.A., Crisp K., Herbert M., Chen S., Malinzak M. Novel approaches to quantify CNS involvement in children with Pompe disease. Neurology. Jun 2020 doi: 10.1212/WNL.0000000000009979. - DOI - PMC - PubMed
    1. Korlimarla A., Lim J.A., Kishnani P.S., Sun B. An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond. Ann Transl Med. 2019;7(13):289. - PMC - PubMed

LinkOut - more resources